Trials / Completed
CompletedNCT04948099
A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A first-in-human study to evaluate the safety and tolerability of escalating, single and multiple ascending doses of VIB1116 in adult participants with rheumatic diseases.
Detailed description
Study acquired from Horizon in 2024. Originally Viela Bio was the sponsor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIB1116 | VIB1116 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2021-07-06
- Primary completion
- 2023-07-03
- Completion
- 2023-07-03
- First posted
- 2021-07-01
- Last updated
- 2024-12-13
Locations
11 sites across 2 countries: United States, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04948099. Inclusion in this directory is not an endorsement.